James F. Young Sells 4,600 Shares of Novavax, Inc. (NASDAQ:NVAX) Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of Novavax stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Novavax Stock Performance

Novavax stock opened at $8.85 on Friday. The firm has a market capitalization of $1.42 billion, a P/E ratio of -3.92 and a beta of 2.07. The company has a 50-day simple moving average of $8.69 and a 200-day simple moving average of $11.34. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. The business’s revenue for the quarter was down 54.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.26) EPS. As a group, sell-side analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On Novavax

Several institutional investors have recently bought and sold shares of the stock. Shah Capital Management lifted its holdings in Novavax by 19.0% in the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after purchasing an additional 1,544,263 shares during the period. State Street Corp lifted its holdings in Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Novavax by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after acquiring an additional 304,159 shares during the last quarter. Bank of Montreal Can lifted its holdings in Novavax by 26.7% in the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after acquiring an additional 517,727 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Novavax by 48.9% in the 3rd quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after acquiring an additional 656,900 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

NVAX has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. B. Riley reiterated a “buy” rating and set a $26.00 target price (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Finally, Jefferies Financial Group lowered their target price on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.